Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Practice
Open Access

Aortitis in a patient on chemotherapy

Sho Fukui, Genki Kidoguchi and Masato Okada
CMAJ November 28, 2022 194 (46) E1574; DOI: https://doi.org/10.1503/cmaj.220584
Sho Fukui
Immuno-Rheumatology Center (Fukui, Kidoguchi, Okada), St. Luke’s International Hospital, Tokyo, Japan; General and Emergency Medicine (Fukui), School of Medicine, Kyorin University, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Genki Kidoguchi
Immuno-Rheumatology Center (Fukui, Kidoguchi, Okada), St. Luke’s International Hospital, Tokyo, Japan; General and Emergency Medicine (Fukui), School of Medicine, Kyorin University, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masato Okada
Immuno-Rheumatology Center (Fukui, Kidoguchi, Okada), St. Luke’s International Hospital, Tokyo, Japan; General and Emergency Medicine (Fukui), School of Medicine, Kyorin University, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading

A 58-year-old woman, who had received her fifth cycle of docetaxel and carboplatin adjuvant chemotherapy for uterine cancer 10 days before admission, was referred to the rheumatology department with persistent fever for 4 days. Eight days before admission, the patient had received granulocyte colony–stimulating factor (G-CSF) for the second time to prevent febrile neutropenia. Upon referral, she had a fever of 38.5°C and slight tenderness in her lower abdomen. Her leukocyte count was 12.6 (reference range 3.0–9.0) × 109/L and C-reactive protein level was 164 (reference < 1.4) mg/L. Contrast-enhanced, whole-body computed tomography (CT) showed no apparent causes of fever. We started treatment with piperacillin–tazobactam for possible abdominal infection. Five days after admission, we ordered another CT scan because the patient’s fever persisted. The subsequent scan showed marked circumferential thickening of the wall of the descending thoracic aorta, suggesting aortitis or periaortitis, which was not present on the original CT scan (Figure 1 and Appendix 1, available at www.cmaj.ca/lookup/doi/10.1503/cmaj.220584/tab-related-content).

Figure 1:
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1:

Contrast-enhanced computed tomography scans of the aorta in a febrile 58-year-old woman who had received granulocyte colony–stimulating factor (GCS-F), docetaxel and carboplatin, (A) 8 days after GCS-F administration, showing normal aorta, and (B) 5 days later, showing all-layer circumferential wall thickness of the descending thoracic aorta suggesting aortitis.

Given the repeated negative results from blood cultures and lack of response to antibiotic treatment, infectious aortitis was unlikely. The patient had no signs of autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus or immunoglobulin G4–related disease. Primary aortitis (e.g., giant cell arteritis) does not typically develop as acutely as observed in this patient. We therefore made a diagnosis of G-CSF- or chemotherapy-induced aortitis. The fever spontaneously subsided within a week, and a CT scan a month later showed improvement (Appendix 1). Aortitis did not recur after an additional cycle of docetaxel and carboplatin without G-CSF.

Chemotherapy agents, such as taxanes or platinum-containing–agents, and G-CSF, particularly polyethylene glycol–conjugated G-CSF, have been reported to be associated with aortitis.1,2 Aortitis induced by G-CSF or chemotherapy typically develops about 1–2 weeks after administration1,3,4 and resolves within a month after medications are stopped. Glucocorticoids may hasten recovery, but we did not administer them to our patient.3,4 Physicians should be aware that CT scans may be normal in the early phase of G-CSF- or chemotherapy-induced aortitis.

Footnotes

  • Competing interests: None declared.

  • This article has been peer reviewed.

  • The authors have obtained patient consent.

This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/

References

  1. ↵
    1. Taimen K,
    2. Heino S,
    3. Kohonen I,
    4. et al
    . Granulocyte colony-stimulating factor-and chemotherapy-induced large-vessel vasculitis: six patient cases and a systematic literature review. Rheumatol Adv Pract 2020;4:rkaa004.
    OpenUrlPubMed
  2. ↵
    1. Oshima Y,
    2. Takahashi S,
    3. Tani K,
    4. et al
    . Granulocyte colony-stimulating factor-associated aortitis in the Japanese Adverse Drug Event Report database. Cytokine 2019;119:47–51.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Lardieri A,
    2. McCulley L,
    3. Jones SC,
    4. et al
    . Granulocyte colony-stimulating factors and aortitis: a rare adverse event. Am J Hematol 2018;93:E333–6.
    OpenUrlPubMed
  4. ↵
    1. Shirai T,
    2. Komatsu H,
    3. Sato H,
    4. et al
    . Migratory aortitis associated with granulocytecolony-stimulating factor. Intern Med 2020;59:1559–63.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 194 (46)
CMAJ
Vol. 194, Issue 46
28 Nov 2022
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Aortitis in a patient on chemotherapy
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Aortitis in a patient on chemotherapy
Sho Fukui, Genki Kidoguchi, Masato Okada
CMAJ Nov 2022, 194 (46) E1574; DOI: 10.1503/cmaj.220584

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Aortitis in a patient on chemotherapy
Sho Fukui, Genki Kidoguchi, Masato Okada
CMAJ Nov 2022, 194 (46) E1574; DOI: 10.1503/cmaj.220584
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Footnotes
    • References
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • A blistering variant of phlegmasia cerulea dolens from underlying squamous cell lung cancer
  • Parechovirus infections in infants
  • Radiation dermatitis in a patient treated for hepatocarcinoma
Show more Practice

Similar Articles

Collections

  • Article Types
    • Clinical Images
  • Topics
    • Cancer & oncology
    • Drugs: adverse reactions
    • Internal medicine
    • Pharmacology & toxicology
    • Rheumatology

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire